FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1023-1030 April 8, 1993 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

The disorders classified as non-Hodgkin's lymphoma are increasing in frequency in the United States, with more than 35,000 cases diagnosed annually. In recent years, there have been numerous advances in our understanding of the biology of these disorders and in their treatment. In this article, these advances will be reviewed in the same order as a physician should consider them when seeing a new patient with non-Hodgkin's lymphoma: the diagnosis is considered first, followed by the prognosis, choice of treatment, and treatment itself.

Clinically Important Subtypes of Non-Hodgkin's Lymphoma

Unlike the related disorder Hodgkin's disease, non-Hodgkin's lymphoma has a firmly established cellular origin with morphologic subtypes . . . [Full Text of this Article]

Factors Predicting Treatment Outcome

Stage

Immunologic Characteristics

Genetic Abnormalities

Tumor-Proliferation Rate

Principles of Therapy

Localized Disease

Disseminated Disease (Bulky Stage II and Stages III and IV)

Therapy in Children

Therapy in Elderly Patients

Therapy in Patients with Human Immunodeficiency Virus Infection

Treatment of Recurrent Disease

Conclusion

Source Information

From the Department of Internal Medicine, University of Nebraska Medical Center, 600 S. 42nd St., Omaha, NE 68198-3332, where reprint requests should be addressed to Dr. Armitage.

References

This article has been cited by other articles:

• Bischof Delaloye, A., Conti, P. S., Gisselbrecht, C., Gregory, S. A. (2009). Introduction. The Oncologist 14: 1-3 [Full Text]  
• Gisselbrecht, C., Vose, J., Nademanee, A., Gianni, A. M., Nagler, A. (2009). Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response. The Oncologist 14: 41-51 [Abstract] [Full Text]  
• Matharu, G., Wilson, D., Sumathi, V., Butt, T. (2009). Spinal cord compression: to biopsy, or not to biopsy?. BMJ Case Reports 2009: bcr0320091657-bcr0320091657 [Abstract] [Full Text]  
• RUSCITTI, C., GUADAGNI, S., RUSSO, F., PALUMBO, G., FIORENTINI, G., MAMBRINI, A., CANTORE, M., KANAVOS, E., PINTO, A., AMICUCCI, G. (2009). Thoracic Stop-flow Perfusion for Refractory Lymphoma: A Phase I-II Evaluation Trial. In Vivo 23: 447-457 [Abstract] [Full Text]  
• Ivanov, A., Krysov, S., Cragg, M. S., Illidge, T. (2008). Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis. Clin. Cancer Res. 14: 4925-4934 [Abstract] [Full Text]  
• Hosing, C., Saliba, R. M., Okoroji, G.-J., Popat, U., Couriel, D., Ali, T., De Padua Silva, L., Kebriaei, P., Alousi, A., De Lima, M., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R. E., Khouri, I. (2008). High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19: 1166-1171 [Abstract] [Full Text]  
• DeNardo, G. L., Natarajan, A., Hok, S., Perkins, J., Cosman, M., DeNardo, S. J., Lightstone, F. C., Mirick, G. R., Miers, L. A., Balhorn, R. L. (2007). Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma. JNM 48: 1338-1347 [Abstract] [Full Text]  
• Leonard, J. P., Coleman, M., Kostakoglu, L., Chadburn, A., Cesarman, E., Furman, R. R., Schuster, M. W., Niesvizky, R., Muss, D., Fiore, J., Kroll, S., Tidmarsh, G., Vallabhajosula, S., Goldsmith, S. J. (2005). Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma. JCO 23: 5696-5704 [Abstract] [Full Text]  
• Czuczman, M.S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L., Bernstein, Z.P., McCarthy, P., Alam, A., Hernandez-Ilizaliturri, F., Skipper, M., Brown, K., Chanan-Khan, A., Klippenstein, D., Loud, P., Rock, M.K., Benyunes, M., Grillo-Lopez, A., Bernstein, S.H. (2005). Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. JCO 23: 694-704 [Abstract] [Full Text]  
• Rodriguez, J., Caballero, M. D., Gutierrez, A., Solano, C., Arranz, R., Lahuerta, J. J., Sierra, J., Gandarillas, M., Perez-Simon, J. A., Zuazu, J., Lopez-Guillermo, A., Sureda, A., Carreras, E., Garcia-Larana, J., Marin, J., Garcia, J. C., Fernandez de Sevilla, A., Rifon, J., Varela, R., Jarque, I., Albo, C., Leon, A., SanMiguel, J., Conde, E. (2004). Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 15: 1504-1509 [Abstract] [Full Text]  
• Bea, S., Colomo, L., Lopez-Guillermo, A., Salaverria, I., Puig, X., Pinyol, M., Rives, S., Montserrat, E., Campo, E. (2004). Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas. JCO 22: 3498-3506 [Abstract] [Full Text]  
• Bertz, H., Zeiser, R., Lange, W., Fetscher, S., Waller, C. F., Finke, J. (2004). Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol 15: 1419-1424 [Abstract] [Full Text]  
• Zidan, J., Hussein, O., Basher, W., Zohar, S. (2004). Serum CA125: A Tumor Marker for Monitoring Response to Treatment and Follow-up in Patients with Non-Hodgkin's Lymphoma. The Oncologist 9: 417-421 [Abstract] [Full Text]  
• Rajendran, J. G., Fisher, D. R., Gopal, A. K., Durack, L. D., Press, O. W., Eary, J. F. (2004). High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes. JNM 45: 1059-1064 [Abstract] [Full Text]  
• Jermann, M., Jost, L. M., Taverna, Ch., Jacky, E., Honegger, H. P., Betticher, D. C., Egli, F., Kroner, Th., Stahel, R. A. (2004). Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 15: 511-516 [Abstract] [Full Text]  
• van Besien, K., Loberiza, F. R. Jr, Bajorunaite, R., Armitage, J. O., Bashey, A., Burns, L. J., Freytes, C. O., Gibson, J., Horowitz, M. M., Inwards, D. J., Marks, D. I., Martino, R., Maziarz, R. T., Molina, A., Pavlovsky, S., Pecora, A. L., Schouten, H. C., Shea, T. C., Lazarus, H. M., Rizzo, J. D., Vose, J. M. (2003). Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102: 3521-3529 [Abstract] [Full Text]  
• Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G. (2003). Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102: 53-59 [Abstract] [Full Text]  
• Levine, J. E., Harris, R. E., Loberiza, F. R. Jr, Armitage, J. O., Vose, J. M., Van Besien, K., Lazarus, H. M., Horowitz, M. M. (2003). A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101: 2476-2482 [Abstract] [Full Text]  
• Kostakoglu, L., Goldsmith, S. J. (2003). 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma. JNM 44: 224-239 [Abstract] [Full Text]  
• Caballero, M. D., Perez-Simon, J. A., Iriondo, A., Lahuerta, J. J., Sierra, J., Marin, J., Gandarillas, M., Arranz, R., Zuazu, J., Rubio, V., Fernandez de Sevilla, A., Carreras, E., Garcia-Conde, J., Garcia-Larana, J., Grande, C., Sureda, A., Vidal, M. J., Rifon, J., Perez-Equiza, C., Varela, R., Moraleda, J. M., Garcia Ruiz, J. C., Albo, C., Cabrera, R., San Miguel, J. F., Conde, E. (2003). High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 14: 140-151 [Abstract] [Full Text]  
• Kaiser, U., Uebelacker, I., Abel, U., Birkmann, J., Trumper, L., Schmalenberg, H., Karakas, T., Metzner, B., Hossfeld, D. K., Bischoff, H. G., Franke, A., Reiser, M., Muller, P., Mantovani, L., Grundeis, M., Rothmann, F., von Seydewitz, C.-U., Mesters, R. M., Steinhauer, E. U., Krahl, D., Schumacher, K., Kneba, M., Baudis, M., Schmitz, N., Pfab, R., Koppler, H., Parwaresch, R., Pfreundschuh, M., Havemann, K. (2002). Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for "Aggressive" Lymphoma. JCO 20: 4413-4419 [Abstract] [Full Text]  
• Branson, K., Chopra, R., Kottaridis, P. D., McQuaker, G., Parker, A., Schey, S., Chakraverty, R. K., Craddock, C., Milligan, D. W., Pettengell, R., Marsh, J. C.W., Linch, D. C., Goldstone, A. H., Williams, C. D., Mackinnon, S. (2002). Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies. JCO 20: 4022-4031 [Abstract] [Full Text]  
• Itoh, K., Ohtsu, T., Fukuda, H., Sasaki, Y., Ogura, M., Morishima, Y., Chou, T., Aikawa, K., Uike, N., Mizorogi, F., Ohno, T., Ikeda, S., Sai, T., Taniwaki, M., Kawano, F., Niimi, M., Hotta, T., Shimoyama, M., Tobinai, K. (2002). Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 13: 1347-1355 [Abstract] [Full Text]  
• Kluin-Nelemans, H. C., Zagonel, V., Anastasopoulou, A., Bron, D., Roozendaal, K. J., Noordijk, E. M., Musson, H., Teodorovic, I., Maes, B., Carbone, A., Carde, P., Thomas, J. (2001). Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study. JNCI J Natl Cancer Inst 93: 22-30 [Abstract] [Full Text]  
• Salven, P., Orpana, A., Teerenhovi, L., Joensuu, H. (2000). Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96: 3712-3718 [Abstract] [Full Text]  
• Stockmeyer, B., Dechant, M., van Egmond, M., Tutt, A. L., Sundarapandiyan, K., Graziano, R. F., Repp, R., Kalden, J. R., Gramatzki, M., Glennie, M. J., van de Winkel, J. G. J., Valerius, T. (2000). Triggering FC{alpha}-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. J. Immunol. 165: 5954-5961 [Abstract] [Full Text]  
• Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., Wahl, R. L. (2000). Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266 [Abstract] [Full Text]  
• Gordon, L. I., Young, M., Weller, E., Habermann, T. M., Winter, J. N., Glick, J., Ghosh, C., Flynn, P., Cassileth, P. A. (1999). A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity. Blood 94: 3307-3314 [Abstract] [Full Text]  
• Blay, J.-Y., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F., Philip, T. (1998). The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: Analysis of the PARMA Trial. Blood 92: 3562-3568 [Abstract] [Full Text]  
• van Besien, K., Sobocinski, K. A., Rowlings, P. A., Murphy, S. C., Armitage, J. O., Bishop, M. R., Chaekal, O.-k., Gale, R. P., Klein, J. P., Lazarus, H. M., McCarthy, P. L. Jr, Raemaekers, J. M.M., Reiffers, J., Phillips, G. L., Schattenberg, A. V.M.B., Verdonck, L. F., Vose, J. M., Horowitz, M. M. (1998). Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma. Blood 92: 1832-1836 [Abstract] [Full Text]  
• Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E., Fisher, R. I. (1998). Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma. NEJM 339: 21-26 [Abstract] [Full Text]  
• Haisma, H. J., Sernee, M. F., Hooijberg, E., Brakenhoff, R. H., Meulen-Muileman, I. H. v.d., Pinedo, H. M., Boven, E. (1998). Construction and Characterization of a Fusion Protein of Single-Chain Anti-CD20 Antibody and Human beta -Glucuronidase for Antibody-Directed Enzyme Prodrug Therapy. Blood 92: 184-190 [Abstract] [Full Text]  
• Rao, P. H., Houldsworth, J., Dyomina, K., Parsa, N. Z., Cigudosa, J. C., Louie, D. C., Popplewell, L., Offit, K., Jhanwar, S. C., Chaganti, R.S.K. (1998). Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma. Blood 92: 234-240 [Abstract] [Full Text]  
• Frickhofen, N., Muller, E., Sandherr, M., Binder, T., Bangerter, M., Wiest, C., Enz, M., Heimpel, H. (1997). Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. Blood 90: 4953-4960 [Abstract] [Full Text]  
• Corradini, P., Astolfi, M., Cherasco, C., Ladetto, M., Voena, C., Caracciolo, D., Pileri, A., Tarella, C. (1997). Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. Blood 89: 724-491 [Abstract] [Full Text]  
• Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.-Y., Harousseau, J.-L., Coiffier, B., Biron, P., Mandelli, F., Chauvin, F. (1995). Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. NEJM 333: 1540-1545 [Abstract] [Full Text]  
• Verdonck, L. F., van Putten, W. L.J., Hagenbeek, A., Schouten, H. C., Sonneveld, P., van Imhoff, G. W., Kluin-Nelemans, H. C., Raemaekers, J. M.M., van Oers, R. H.J., Haak, H. L., Schots, R., Dekker, A. W., de Gast, G. C., Lowenberg, B. (1995). Comparison of CHOP Chemotherapy with Autologous Bone Marrow Transplantation for Slowly Responding Patients with Aggressive Non-Hodgkin's Lymphoma. NEJM 332: 1045-1051 [Abstract] [Full Text]  
• Offit, K., Coco, F. L., Louie, D. C., Parsa, N. Z., Leung, D., Portlock, C., Ye, B. H., Lista, F., Filippa, D. A., Rosenbaum, A., Ladanyi, M., Jhanwar, S., Dalla-Favera, R., Chaganti, R.S.K. (1994). Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma. NEJM 331: 74-80 [Abstract] [Full Text]  
• Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., Bernstein, I. D. (1993). Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support. NEJM 329: 1219-1224 [Abstract] [Full Text]  
• Longo, D. L., DeVita, V. T., Young, R. C., Salloum, E., Levin, M., Fisher, R. I. (1993). CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. NEJM 329: 580-582 [Full Text]